Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arsenic Poisoning | 4 | 2014 | 103 | 0.470 |
Why?
|
| Arsenic | 5 | 2014 | 251 | 0.470 |
Why?
|
| Environmental Exposure | 4 | 2014 | 296 | 0.430 |
Why?
|
| Bangladesh | 9 | 2014 | 318 | 0.340 |
Why?
|
| Drinking Water | 2 | 2013 | 64 | 0.280 |
Why?
|
| Pancreatic Neoplasms | 3 | 2015 | 645 | 0.250 |
Why?
|
| Carcinoma | 3 | 2012 | 436 | 0.240 |
Why?
|
| Food Contamination | 1 | 2013 | 31 | 0.240 |
Why?
|
| Oryza | 1 | 2013 | 40 | 0.230 |
Why?
|
| Respiration Disorders | 1 | 2013 | 39 | 0.230 |
Why?
|
| Smoking | 2 | 2014 | 609 | 0.220 |
Why?
|
| Water Pollutants, Chemical | 1 | 2013 | 135 | 0.210 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2012 | 33 | 0.210 |
Why?
|
| Genome-Wide Association Study | 4 | 2014 | 1620 | 0.200 |
Why?
|
| Colorectal Neoplasms | 3 | 2014 | 938 | 0.190 |
Why?
|
| Spectrum Analysis | 3 | 2015 | 118 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2356 | 0.170 |
Why?
|
| Skin Diseases | 2 | 2013 | 166 | 0.160 |
Why?
|
| Lung | 1 | 2013 | 1170 | 0.150 |
Why?
|
| Duodenoscopy | 1 | 2015 | 8 | 0.140 |
Why?
|
| Fiber Optic Technology | 1 | 2015 | 35 | 0.130 |
Why?
|
| Duodenum | 1 | 2015 | 100 | 0.130 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 9 | 0.120 |
Why?
|
| Environmental Pollutants | 1 | 2014 | 51 | 0.120 |
Why?
|
| Telomere | 1 | 2014 | 108 | 0.120 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2013 | 43 | 0.120 |
Why?
|
| Arsenicals | 1 | 2013 | 48 | 0.120 |
Why?
|
| Scattering, Radiation | 1 | 2013 | 114 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 1 | 2014 | 130 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 103 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2013 | 182 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 296 | 0.110 |
Why?
|
| Middle Aged | 10 | 2015 | 25017 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2014 | 263 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2013 | 195 | 0.100 |
Why?
|
| Biopsy | 2 | 2013 | 1161 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 770 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 576 | 0.100 |
Why?
|
| Adult | 9 | 2015 | 25640 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 479 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 797 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2011 | 126 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2014 | 628 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1920 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2011 | 264 | 0.090 |
Why?
|
| Adenoma | 1 | 2011 | 235 | 0.080 |
Why?
|
| Female | 12 | 2015 | 44507 | 0.080 |
Why?
|
| Humans | 18 | 2015 | 86601 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1169 | 0.080 |
Why?
|
| Young Adult | 4 | 2014 | 5974 | 0.080 |
Why?
|
| Adolescent | 5 | 2014 | 8979 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 1204 | 0.080 |
Why?
|
| Male | 10 | 2015 | 40956 | 0.080 |
Why?
|
| Colon | 1 | 2011 | 496 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 678 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1464 | 0.070 |
Why?
|
| Chondromatosis | 1 | 1993 | 2 | 0.060 |
Why?
|
| Leiomyoma, Epithelioid | 1 | 1993 | 2 | 0.060 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 1993 | 12 | 0.060 |
Why?
|
| Areca | 1 | 2013 | 9 | 0.060 |
Why?
|
| Mediastinal Neoplasms | 1 | 1993 | 46 | 0.060 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 136 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1993 | 100 | 0.060 |
Why?
|
| Aged | 5 | 2015 | 18402 | 0.060 |
Why?
|
| Endoscopy, Digestive System | 2 | 2012 | 65 | 0.050 |
Why?
|
| Smoking Cessation | 1 | 2014 | 230 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2014 | 4210 | 0.050 |
Why?
|
| Stomach Neoplasms | 1 | 1993 | 266 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1019 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2887 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1804 | 0.050 |
Why?
|
| Prevalence | 1 | 2013 | 1239 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2014 | 1078 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1961 | 0.040 |
Why?
|
| Incidence | 1 | 2013 | 1576 | 0.040 |
Why?
|
| Genotype | 2 | 2014 | 1850 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1673 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1937 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1384 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2767 | 0.040 |
Why?
|
| Appendicitis | 1 | 1988 | 62 | 0.040 |
Why?
|
| Duodenoscopes | 1 | 2015 | 7 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 35 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2270 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 94 | 0.030 |
Why?
|
| Selenium | 1 | 2014 | 44 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 91 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 151 | 0.030 |
Why?
|
| Risk Factors | 2 | 2015 | 5416 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 406 | 0.030 |
Why?
|
| Cacodylic Acid | 1 | 2013 | 22 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 81 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 202 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 751 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 185 | 0.030 |
Why?
|
| Jaundice, Obstructive | 1 | 2012 | 10 | 0.030 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2013 | 201 | 0.030 |
Why?
|
| Light | 1 | 2013 | 289 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2012 | 22 | 0.030 |
Why?
|
| Gallbladder | 1 | 2012 | 30 | 0.030 |
Why?
|
| Electroporation | 1 | 2012 | 55 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 70 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2012 | 34 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 857 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 2012 | 68 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2012 | 121 | 0.030 |
Why?
|
| Optical Phenomena | 1 | 2011 | 7 | 0.030 |
Why?
|
| Colonoscopes | 1 | 2011 | 11 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 2012 | 97 | 0.030 |
Why?
|
| Drainage | 1 | 2012 | 157 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1993 | 2261 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 102 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2012 | 119 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 179 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1127 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 554 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 387 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 213 | 0.020 |
Why?
|
| Video Recording | 1 | 2011 | 190 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 328 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 541 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 394 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 377 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2012 | 238 | 0.020 |
Why?
|
| DNA | 1 | 2014 | 1294 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1685 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 2377 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 469 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1351 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 1056 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2261 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 534 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1565 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 1990 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1267 | 0.010 |
Why?
|
| Syndrome | 1 | 1993 | 446 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 3967 | 0.010 |
Why?
|
| Child | 2 | 1993 | 6926 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1988 | 63 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 1988 | 216 | 0.010 |
Why?
|
| Acute Disease | 1 | 1988 | 826 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1988 | 695 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1988 | 3611 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1988 | 8475 | 0.000 |
Why?
|